IFN-α Confers Resistance of Systemic Lupus Erythematosus Nephritis to Therapy in NZB/W F1 Mice
- 1 August 2011
- journal article
- research article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 187 (3), 1506-1513
- https://doi.org/10.4049/jimmunol.1004142
Abstract
The critical role of IFN-α in the pathogenesis of human systemic lupus erythematosus has been highlighted in recent years. Exposure of young lupus-prone NZB/W F1 mice to IFN-α in vivo leads to an accelerated lupus phenotype that is dependent on T cells and is associated with elevated serum levels of BAFF, IL-6, and TNF-α, increased splenic expression of IL-6 and IL-21, formation of large germinal centers, and the generation of large numbers of short-lived plasma cells that produce IgG2a and IgG3 autoantibodies. In this study, we show that both IgG2a and IgG3 autoantibodies are pathogenic in IFN-α–accelerated lupus, and their production can be dissociated by using low-dose CTLA4-Ig. Only high-dose CTLA4-Ig attenuates both IgG2a and IgG3 autoantibody production and significantly delays death from lupus nephritis. In contrast, BAFF/APRIL blockade has no effect on germinal centers or the production of IgG anti-dsDNA Abs but, if given at the time of IFN-α challenge, delays the progression of lupus by attenuating systemic and renal inflammation. Temporary remission of nephritis induced by combination therapy with cyclophosphamide, anti-CD40L Ab, and CTLA4-Ig is associated with the abrogation of germinal centers and depletion of short-lived plasma cells, but relapse occurs more rapidly than in conventional NZB/W F1 mice. This study demonstrates that IFN-α renders NZB/W F1 relatively resistant to therapeutic intervention and suggests that the IFN signature should be considered when randomizing patients into groups and analyzing the results of human clinical trials in systemic lupus erythematosus.Keywords
This publication has 53 references indexed in Scilit:
- Interferon‐α induces unabated production of short‐lived plasma cells in pre‐autoimmune lupus‐prone (NZB×NZW)F1 mice but not in BALB/c miceEuropean Journal of Immunology, 2011
- Interferon‐α accelerates murine systemic lupus erythematosus in a T cell–dependent mannerArthritis & Rheumatism, 2010
- Intrinsic Properties of immunoglobulin IgG1 Isotype-Switched B Cell Receptors Promote Microclustering and the Initiation of SignalingImmunity, 2010
- Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 miceArthritis & Rheumatism, 2010
- Interferon‐regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation studyArthritis & Rheumatism, 2009
- Virus Binding to a Plasma Membrane Receptor Triggers Interleukin-1α-Mediated Proinflammatory Macrophage Response In VivoImmunity, 2009
- Interferon‐α treatment of female (NZW × BXSB)F1 mice mimics some but not all features associated with the Yaa mutationArthritis & Rheumatism, 2009
- Prevention of murine antiphospholipid syndrome by BAFF blockadeArthritis & Rheumatism, 2008
- Systemic IFN‐α drives kidney nephritis in B6.Sle123 miceEuropean Journal of Immunology, 2008
- Anti‐chromatin antibodies drive in vivo antigen‐specific activation and somatic hypermutation of rheumatoid factor B cells at extrafollicular sitesEuropean Journal of Immunology, 2007